BeiGene P/E Ratio

BeiGene (BGNE) currently reports a P/E ratio of 26.97. That is above the Healthcare sector average of 25.75. Use the charts on this page to explore BeiGene's P/E ratio history and peer comparisons.

BeiGene's P/E ratio of 26.97 is higher than the Healthcare sector average of 25.75. That is roughly 4.7% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

The P/E ratio is a valuation multiple that relates BeiGene's market price to a fundamental measure such as earnings, sales, or book value. At 26.97, BGNE can look expensive or cheap only in context — versus its own history, growth rate, and Healthcare peers. Higher multiples often price in stronger expected growth; lower ones can signal value or concern.

Start with the current P/E ratio of 26.97, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 25.75. From there, open related valuation or income-statement pages for BeiGene, and consider following BGNE for alerts when major investors trade the stock.

BeiGene is classified in the Healthcare sector. On P/E ratio, it currently shows 26.97 versus a sector average near 25.75. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing BGNE with unrelated industries.